Autologous hair follicle stem cell-derived secretome, known as aHFS, substantially outperforms standard platelet-rich plasma across key growth-factor, exosome, and clinical recovery metrics, according to clinical data presented by Dr. Alan J. The findings are scheduled for presentation at the 34th World Congress of the International Society of Hair Restoration Surgery, held October 15–17, 2026, in Rio de Janeiro, Brazil.
Comparative Proteomic and Exosome Findings
According to data detailed by Bauman Medical, aHFS is produced from a patient’s own hair follicle stem cells and mesenchymal stem cells. These cells are collected through non-invasive hair follicle plucking or routine follicular unit extraction, then processed using a patented expansion method developed by Acorn Biolabs. The resulting cell-free formulation contains paracrine factors including growth factors, exosomes, extracellular matrix proteins, and cytokines.
In analytical comparisons against autologous PRP prepared via standard double-spin centrifugation from the same donors, the study profiled 37 regenerative molecules using mass spectrometry, multiplex ELISA, and nanoparticle tracking analysis:
- Hair Regrowth Metrics: Matrix molecules crucial for follicle anchorage and cycling—such as aggrecan, collagens, and keratins—reached up to 22 times higher concentrations in aHFS than in PRP. Growth factors including GDNF, bFGF/FGF2, and KGF/FGF7 reached up to 11 times higher levels, while supportive cytokines MCP-1 and SDF-1 reached 4 times higher concentrations, according to the data.
- Skin and Scalp Rejuvenation: Matrix molecules such as fibronectin, emilin, and collagen reached up to 34 times higher concentrations. Growth factors including VEGF, GDNF, PEDF, and bFGF reached up to 23 times higher levels, HAPLN1 protein reached 12 times higher concentrations, and supportive cytokines reached up to 9 times higher levels.
- Exosome Profile: Samples of aHFS averaged 5 billion exosome particles per sample with a modal size of 137 nm and approximately 14 mg/mL protein content, factors largely absent from plasma-based therapies.
Addressing Age-Related Potency Decline
A primary limitation of traditional autologous treatments has been the reliance on blood plasma constituents that degrade with age. According to the data, aHFS maintained robust IGF-1 and IGFBP3 levels independently of donor age while demonstrating significantly lower levels of pro-inflammatory markers such as MMP-1 and MMP-2 compared to standard PRP preparations.
“PRP has been a useful tool for years, but its performance has always been limited by what’s naturally present in a patient’s blood plasma—and that declines with age,” said Dr. Alan J. Bauman, board-certified hair restoration physician and founder of Bauman Medical in Boca Raton, Florida, as reported by GlobeNewswire. “aHFS is a fundamentally different approach: it draws directly from the patient’s own hair follicle stem”
Clinical Recovery and Patient Experience
Beyond hair restoration metrics, preliminary findings from a post-ablative laser recovery study involving 11 patients evaluated the efficacy of aHFS in skin healing. According to the published abstract, aHFS treatment yielded the following outcomes compared to best-in-class comparators:
- Reductions in recovery symptoms—including pain, itching, crusting, swelling, and redness—ranging from 32% to 58%.
- A 39% improvement in cosmetic appearance.
- A 63% improvement in skin feel.
- A 12 times higher likelihood of being rated as the best overall patient experience compared to standard care.
Longer-term efficacy data regarding these applications are currently being gathered through an ongoing multicenter observational trial registered at ClinicalTrials.gov under identifier NCT06477172.
Keep reading